NEW YORK (GenomeWeb News) – Shares of Illumina's stock rose as much as 9 percent today following a report that the San Diego-based genetic analysis tools firm and Roche may have agreed to a deal for Roche to acquire Illumina for $66 per share, or approximately $8.14 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.